Replies to post #56274 on BrewBilt Brewing Co (BRBL)

[eck]

GW Pharma would be a nice fit.

GW Pharmaceuticals (NASDAQ: GWPH)
This British company, also listed on the London Stock Exchange, has been licensed by the UK's Home Office to “work with a range of controlled drugs for medical research purposes.”
GW’s flagship product, Sativex, a cannabinoid medicine, has been approved or recommended for approval in 24 countries as a treatment for severe spasticity because of multiple sclerosis.
This past June, the company announced an agreement with New York state to begin clinical trials for the use of cannabidiols to help children suffering from epileptic seizures.
And last November the FDA granted Orphan Drug status to GW Pharmaceuticals' Epidiolex, the company's CBD-based treatment for children with Dravet Syndrome, a rare and severe form of drug-resistent epilepsy